January 19, 1999 – After two Chinese research studies suggested that arsenic trioxide could induce complete remission in patients with acute promyeloblastic leukemia (AML), American research confirms that this unconventional product does indeed have the advertised results.
The study that was undertaken to understand the mechanism of action of arsenic trioxide, a highly toxic product in high doses, was carried out in 12 people with AML, who had relapsed after extensive therapy. The researchers treated them with doses ranging from 0.06 to 0.2 mg / kg until the visible leukemia cells were completely gone from the bone marrow. A whole battery of tests has confirmed that arsenic trioxide causes the intracellular destruction (apoptosis) of leukemia cells.
Of the 12 patients studied, 11 had complete remission after treatment which lasted between 12 and 39 days with cumulative doses of arsenic trioxide ranging from 160 to 515 mg. However, three of them relapsed.
One commentator notes that it is encouraging to see “alternative” therapies continually appearing to the usual clinical approaches, although they remain within the conventional medical paradigm. As is known, ingestion of high doses of arsenic is associated with cancer, however at low doses the same product can treat cancer.
HealthPassport.net
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998 Nov 5; 339 (19): 1341-8
